CN114174296A - 作为激酶抑制剂的多环化合物 - Google Patents

作为激酶抑制剂的多环化合物 Download PDF

Info

Publication number
CN114174296A
CN114174296A CN202180004135.3A CN202180004135A CN114174296A CN 114174296 A CN114174296 A CN 114174296A CN 202180004135 A CN202180004135 A CN 202180004135A CN 114174296 A CN114174296 A CN 114174296A
Authority
CN
China
Prior art keywords
compound
group
cancer
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180004135.3A
Other languages
English (en)
Other versions
CN114174296B (zh
Inventor
张汉承
程鑫
贾薇
蔡聪聪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Hangzhou Innogate Pharma Co Ltd
Original Assignee
Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Hangzhou Innogate Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd, CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd, Hangzhou Innogate Pharma Co Ltd filed Critical Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
Priority to CN202410275081.XA priority Critical patent/CN118255761A/zh
Publication of CN114174296A publication Critical patent/CN114174296A/zh
Application granted granted Critical
Publication of CN114174296B publication Critical patent/CN114174296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供了一类作为激酶抑制剂的多环化合物。具体地，本发明提供了如下式(I)所示结构的化合物(各基团定义如说明书中所述)、含有式(I)化合物的药物组合物及所述化合物，以及这些化合物的其光学异构体，药学上可接受的盐，前药，氘代形式，水合物，溶剂合物等等。其能够有效抑制包括CDK和/或TRK在内的多种激酶，从而起到治疗各种肿瘤等相关多种疾病的作用。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180004135.3A 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物 Active CN114174296B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410275081.XA CN118255761A (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020100279138 2020-01-10
CN202010027913 2020-01-10
PCT/CN2021/071144 WO2021139817A1 (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410275081.XA Division CN118255761A (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物

Publications (2)

Publication Number Publication Date
CN114174296A true CN114174296A (zh) 2022-03-11
CN114174296B CN114174296B (zh) 2024-01-23

Family

ID=76788032

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180004135.3A Active CN114174296B (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物
CN202410275081.XA Pending CN118255761A (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410275081.XA Pending CN118255761A (zh) 2020-01-10 2021-01-11 作为激酶抑制剂的多环化合物

Country Status (9)

Country Link
US (1) US20230095043A1 (zh)
EP (1) EP4089092A4 (zh)
JP (1) JP7519712B2 (zh)
KR (1) KR20220140731A (zh)
CN (2) CN114174296B (zh)
AU (1) AU2021206100B2 (zh)
CA (1) CA3164345A1 (zh)
TW (1) TWI795706B (zh)
WO (1) WO2021139817A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118252835A (zh) * 2022-12-26 2024-06-28 石药集团中奇制药技术（石家庄）有限公司 一种cdk抑制剂的用途
WO2024153053A1 (zh) * 2023-01-17 2024-07-25 石药集团中奇制药技术（石家庄）有限公司 Cdk抑制剂及其可药用盐的晶型以及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030439A1 (en) * 2014-08-28 2016-03-03 Ratiopharm Gmbh Method of producing palbociclib and pharmaceutical compositions comprising the same
WO2018108084A1 (zh) * 2016-12-12 2018-06-21 杭州英创医药科技有限公司 一类含有三环杂芳基的化合物
CN108699055A (zh) * 2015-12-13 2018-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
US20190031642A1 (en) * 2013-10-18 2019-01-31 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202114689A (zh) * 2019-08-06 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190031642A1 (en) * 2013-10-18 2019-01-31 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016030439A1 (en) * 2014-08-28 2016-03-03 Ratiopharm Gmbh Method of producing palbociclib and pharmaceutical compositions comprising the same
CN108699055A (zh) * 2015-12-13 2018-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
WO2018108084A1 (zh) * 2016-12-12 2018-06-21 杭州英创医药科技有限公司 一类含有三环杂芳基的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗蕴, 胡永洲: "细胞周期蛋白依赖性激酶抑制剂", 中国现代应用药学, no. 05, pages 360 - 363 *

Also Published As

Publication number Publication date
CA3164345A1 (en) 2021-07-15
WO2021139817A1 (zh) 2021-07-15
CN118255761A (zh) 2024-06-28
TWI795706B (zh) 2023-03-11
JP2023509994A (ja) 2023-03-10
KR20220140731A (ko) 2022-10-18
EP4089092A4 (en) 2024-03-06
AU2021206100B2 (en) 2024-07-04
CN114174296B (zh) 2024-01-23
JP7519712B2 (ja) 2024-07-22
EP4089092A1 (en) 2022-11-16
US20230095043A1 (en) 2023-03-30
AU2021206100A1 (en) 2022-08-18
TW202140472A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
KR102236605B1 (ko) 피리도피리미딘온 cdk2/4/6 억제제
CN110746443B (zh) 一类含有三环杂芳基的化合物
CN107995911B (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
BR112016020621B1 (pt) Composto, composição farmacêutica, inibidor de atividade da enzima ezh1 e/ou ezh2, agente terapêutico para tumores, e, agente antitumor
CN111393431A (zh) 谷氨酰胺酶抑制剂
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
AU2016348620A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2020140054A1 (en) Cyclin-dependent kinase inhibitors
CN114174296A (zh) 作为激酶抑制剂的多环化合物
CN102711766A (zh) N-9-取代的嘌呤化合物、组合物和使用方法
CN111936465A (zh) 作为共价menin抑制剂的哌啶化合物
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN112300153A (zh) 一种杂环化合物、药物组合物和用途
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
CN109790160B (zh) 吡啶并五元芳香环类化合物、其制备方法及用途
US20230174545A1 (en) Heterocyclic compounds as bet inhibitors
WO2018097162A1 (ja) クマリン骨格を有するスルホンアミド誘導体
CN113242858A (zh) 一类蛋白受体激酶抑制剂的制备和应用
CN113583026B (zh) 一类含有稠合三环结构的化合物
US20240140947A1 (en) Compound for the treatment of cancer
CN115611897A (zh) 作为rsk2抑制剂的化合物及其应用
US20240067662A1 (en) Kras inhibitors
CN117659020A (zh) 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2023034808A1 (en) Mixed lineage kinase inhibitors and methods of use
WO2022236253A1 (en) Heterocyclic compounds as kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061272

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant